ID   SCH
AC   CVCL_1687
DR   BTO; BTO:0005929
DR   CLO; CLO_0037148
DR   EFO; EFO_0002856
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1008
DR   BioSample; SAMN03471666
DR   cancercelllines; CVCL_1687
DR   Cell_Model_Passport; SIDM00383
DR   ChEMBL-Cells; CHEMBL3308783
DR   ChEMBL-Targets; CHEMBL1075573
DR   Cosmic; 801343
DR   Cosmic; 909711
DR   Cosmic; 1187290
DR   Cosmic-CLP; 909711
DR   DepMap; ACH-002198
DR   EGA; EGAS00001000978
DR   GDSC; 909711
DR   GEO; GSM552371
DR   GEO; GSM562417
DR   GEO; GSM827269
DR   GEO; GSM1670414
DR   IARC_TP53; 4347
DR   JCRB; JCRB0251
DR   LINCS_LDP; LCL-1148
DR   PharmacoDB; SCH_1359_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1687
DR   PubChem_Cell_line; CVCL_1687
DR   Wikidata; Q54952424
RX   CelloPub=CLPUB00141;
RX   CelloPub=CLPUB00142;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1007/0-306-46861-1_8;
RX   PubMed=1170940;
RX   PubMed=2878840;
RX   PubMed=6682628;
RX   PubMed=7819056;
RX   PubMed=9290701;
RX   PubMed=11014955;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 54 hours (CelloPub=CLPUB00142); 36-37 hours (CelloPub=CLPUB00584); ~1.5 days (Note=Lot 07022010) (JCRB=JCRB0251).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249dup (c.745_747dupAGG) (p.Arg249_Pro250insArg) (c.747_748insAGG); Zygosity=Heterozygous (PubMed=7819056; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=77.74%; East Asian, South=22.24%; South Asian=0.01%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 9
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C95749; Gastric choriocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   CelloPub=CLPUB00141;
RA   Tanaka K.;
RT   "Establishment and characterisation of cultured cell lines of human
RT   choriocarcinoma origin.";
RL   Niigata Igakkai Zasshi 95:95-105(1981).
//
RX   CelloPub=CLPUB00142;
RA   Tanaka K., Takeuchi S.;
RT   "Cell culture of choriocarcinoma.";
RL   Tissue Cult. 6:471-478(1980).
//
RX   CelloPub=CLPUB00584;
RA   Motoyama T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1007/0-306-46861-1_8;
RA   Ganapathy V., Prasad P.D., Leibach F.H.;
RT   "Choriocarcinoma.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.141-147; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=1170940;
RA   Kameya T., Kuramoto H., Suzuki K., Kenjo T., Oshikiri T., Hayashi H.,
RA   Itakura M.;
RT   "A human gastric choriocarcinoma cell line with human chorionic
RT   gonadotropin and placental alkaline phosphatase production.";
RL   Cancer Res. 35:2025-2032(1975).
//
RX   PubMed=2878840; DOI=10.1016/0020-7292(86)90088-3;
RA   Yamashita K., Nakamura T., Shimizu T., Katagiri M., Ikeda H.;
RT   "Expression of HLA class I and class II antigens in human
RT   choriocarcinoma cell lines.";
RL   Int. J. Gynecol. Obstet. 24:301-307(1986).
//
RX   PubMed=6682628; DOI=10.1016/0002-9378(83)90927-4;
RA   Sekiya S., Kaiho T., Shirotake S., Iwasawa H., Takeda B.,
RA   Takamizawa H.;
RT   "Effect of methotrexate on the growth and human chorionic gonadotropin
RT   secretion of human choriocarcinoma cell lines in vitro.";
RL   Am. J. Obstet. Gynecol. 146:57-64(1983).
//
RX   PubMed=7819056; DOI=10.1038/bjc.1995.3;
RA   Yaginuma Y., Yamashita T., Takuma N., Katayama H., Ishikawa M.;
RT   "Analysis of the p53 gene in human choriocarcinoma cell lines.";
RL   Br. J. Cancer 71:9-12(1995).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11014955; DOI=10.1159/000010310;
RA   Takayanagi T., Aoki Y., Tanaka K.;
RT   "Expression of constitutively active c-MET receptor in human
RT   choriocarcinoma.";
RL   Gynecol. Obstet. Invest. 50:198-202(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//